



LISTING OF THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1.-18. (Canceled)

19. (Currently Amended) A use of a pharmaceutical composition comprising one or more steroids, which are not cytostaticum, conjugated with mammalian proteins and a cytoskeleton-acting drug according to claim 13, for the treatment of solid cancer or haematological malignancies.

20. (Previously Presented) The use according to claim 19, wherein the solid cancer is selected from the group consisting of: prostate adenocarcinoma (hormone sensitive or resistant) and its metastases, breast cancer and its metastases in any places, pheochromocytomas and their metastases, bone tumor and their metastases and brain tumor (neuroblastomas).

21. (Previously Presented) The use according to claim 19, wherein the haematological malignancies are selected from the group consisting of: acute and chronic myeloid leukaemia, acute and chronic lymphoid leukaemia and lymphomas (B and T).

22.-27. (Canceled)

28. (New) A method for treating a solid cancer or haematological malignancy in a patient comprising administering a composition comprising one or more steroids which are not cytostaticum, wherein the composition is conjugated with a mammalian protein, the composition further comprising a cytoskeleton-acting drug.

29. (New) The method of claim 28, wherein the solid cancer is one of prostate adenocarcinoma (hormone sensitive or resistant) and its metastases, breast cancer and its metastases in any places, pheochromocytomas and their metastases, bone tumor and their metastases and brain tumor (neurobastomas).

30. (New) The method of claim 28, wherein the haematological malignancies are acute and chronic myeloid leukemia, acute and chronic lymphoid leukemia and lymphomas (B and T).

31. (New) The method of claim 28, wherein the steroid is an androgen.

32. (New) The method of claim 31, wherein the androgen is testosterone.

33. (New) The method of claim 28, wherein the mammalian protein is a recombinant or isolated natural serum albumin.

34. (New) The method of claim 28, wherein the composition is detectably-labeled.

35. (New) The method of claim 32, wherein the testosterone is covalently attached to the mammalian protein through a carboxy-methyl ether linker.

36. (New) The method of claim 35, wherein the linker is covalently attached to the testosterone at the 3' position of the steroidal ring.

37. (New) The method of claim 28, wherein the cytoskeleton-acting drug is Taxol or Taxotere.

38. (New) The method of claim 28, the composition further comprises an antiandrogen.

39. (New) The method of claim 38, wherein the antiandrogen is present in about a 10-fold molar excess relative to the molar amount of the one more steroid.

40. (New) The method of claim 28, wherein the administration of the composition is paraenteral, percutaneous or intravenous.

41. (New) The method of claim 28, wherein the composition is administered at least once daily.

42. (New) The method of claim 28, wherein the method further comprises the step of administering an antiandrogen to the patient.

43. (New) The method of claim 28, wherein the method further comprises the step of decreasing solid cancer mass in the patient.

44. (New) A method for treating prostate cancer in a patient, the method comprising the step of administering a composition comprising a compound with the following formula: [Testosterone3-(O-carboxymethyl)oxime-human serum albumin], the composition further comprising Taxol or Taxotere.

45. (New) The method of claim 44, wherein the composition further comprises an antiandrogen.

46. (New) The method of claim 44, wherein the method further comprises the step of administering an antiandrogen to the patient.

47. (New) The method of claim 44, wherein the method further comprises the step of decreasing prostate cancer mass in the patient.